Involvement of ET-1 in diabetic cardiomyopathy, vascular abnormality and nepropathy which are regressed by a novel endothelin receptor antagonist Dajisentan.

AIM: An impaired endothelium contributes to diabetic cardiomyopathy (CMP), vascular pathy (VSP) and nephropathy (NPP) in diabetes. It is hypothesized that these disorders which are the consequence to damaged endothelium could be recovered by Dajisentan, a novel dual endothelin receptor antagonist, developed by us as an investigated new drug. METHODS: Rat diabetes model was developed by ip streptozotocin and the